This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock

Eversept Partners purchased 2,252,202 Avantor shares in Q4 (estimated $27.72M using quarterly average pricing), raising its quarter-end stake to 3,176,644 shares worth $36.40M (≈1.83% of reported U.S. equity holdings). Avantor shares were $7.80 as of Friday, down ~50% over the past year; FY2025 revenue was $6.55B (down 3% YoY) and net loss was $530.2M versus a $711.5M profit in 2024. The trade signals investor interest in execution of Avantor’s “Revival” turnaround, but weak fundamentals and the large recent share-price decline imply continued execution risk for holders.

Analysis

Eversept’s accumulation is best read as a thematic, life‑science ecosystem play rather than a macro trade — the fund’s portfolio clustering implies they value exposure to lab‑consumables distribution and services optionality versus pure biotech binary risk. If the Revival program meaningfully improves e‑commerce penetration and go‑to‑market efficiency, 200–400bps of incremental EBIT margin is realistic within 12–24 months because fixed logistics and procurement leverage can be redeployed across higher‑margin service lines.

Second‑order winners include specialty chemical suppliers and contract packaging partners that would see steadier, larger volume orders if Avantor re‑wins enterprise procurement deals; conversely, commodity distributors and low‑touch catalog players could see compressing volumes and price pressure. A successful turnaround would also raise M&A odds — private equity typically values stable, cash‑generative distributors at materially higher multiples, creating a plausible take‑private path over a 2–4 year horizon.

Key risks are execution and revenue mix: loss of a few large biotech accounts or continued margin erosion from intensified e‑procurement competition would rapidly vaporize upside, making the next 3–9 months a binary execution window. Market sentiment is pricing high operational failure risk, which creates asymmetric payoff for disciplined, time‑limited exposures but mandates tight sizing and explicit hedges against downside scenarios.

From a technical/flow standpoint, this name is likely to see episodic volatility around earnings and any announced contract renewals; activist/strategic investors could add in tranches tied to concrete KPIs (e‑commerce penetration, gross margin stabilization). That makes staged entry, event‑linked sizing, and option‑based defined‑risk structures the most efficient ways to harvest the potential re‑rating while capping loss if the Revival stalls.

Key Decisions for Investors

• Event‑linked long equity (AVTR): Build a 1.5% NAV position in two tranches (50% now, 50% on failed next quarterly revenue guide vs management targets). Hard stop at 30% drawdown from entry; target 2x upside in 12–24 months conditional on margin improvement metrics (e‑commerce growth + gross margin stabilization).
• Defined‑risk option spread (AVTR): Buy 18‑month call spread sized to 0.75% NAV (long 100–200% OTM call, short a higher OTM call) to capture asymmetric upside if turnaround executes while limiting premium loss to 100% of spend; look for 3:1+ upside/downside payoff if shares re‑rate.
• Pair trade to isolate execution risk: Long AVTR cash equal‑notional / Short DHR (or TMO) 0.25x notional to reduce broad life‑science demand beta. Timeframe 12–24 months; reduces sector cyclicality while keeping upside from Avantor’s idiosyncratic recovery.
• Event short catalyst hedge: Buy 6–9 month puts sized to 0.5% NAV or sell covered calls against new long to finance hedges ahead of the next two earnings releases if management guidance lacks concrete KPIs (e‑commerce penetration, retention of top customers).
• Monitor for M&A signal: If a strategic buyer PE or competitor is reported in diligence or if two consecutive quarters show >200bps margin improvement, consider adding to long and layering in long‑dated calls (24 months) to capture a potential take‑private or multiple expansion scenario.